Lenalidomide, dexamethasone (DrugBank: Lenalidomide, Dexamethasone)
1 disease告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
16 | クロウ・深瀬症候群 | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT01816620 (ClinicalTrials.gov) | March 2014 | 14/3/2013 | Study to Evaluate Lenalidomide Plus Dexamethasone in Patients With Newly Diagnosed POEMS Syndrome | An Open-label Phase II Study to Determine the Efficacy and Safety of Lenalidomide Plus Dexamethasone (LDex) in Patients With Newly Diagnosed POEMS Syndrome | POEMS Syndrome | Drug: Lenalidomide, Dexamethasone | Peking Union Medical College Hospital | Celgene Corporation | Completed | 18 Years | N/A | All | 41 | Phase 2 | China |